Literature DB >> 16091479

Epicardial adipose tissue and insulin resistance in obese subjects.

Gianluca Iacobellis1, Frida Leonetti.   

Abstract

CONTEXT: Epicardial adipose tissue has been recently recognized as a source of bioactive molecules as well as free fatty acids, adiponectin, and inflammatory cytokines. Epicardial fat reflects intraabdominal visceral fat, and the echocardiographic assessment of this tissue is an easy and reliable marker of visceral adiposity.
OBJECTIVE: In this study we evaluated whether epicardial adipose tissue is related to insulin sensitivity and glucose metabolism in obese subjects. PATIENTS: Thirty obese subjects (20 women and 10 men; mean age, 40.8 +/- 11.5 yr; body mass index, 43 +/- 9.1 kg/m2) were included in this study. No subject was taking drugs or had a history or evidence of metabolic, cardiovascular, respiratory, or hepatic disease. MAIN OUTCOME MEASURES: Each subject underwent a transthoracic echocardiogram to evaluate epicardial adipose tissue thickness, a euglycemic hyperinsulinemic clamp to estimate insulin sensitivity, and an oral glucose tolerance test to evaluate glucose tolerance.
RESULTS: The thickness of the epicardial adipose tissue on the right ventricle varied between 4 and 17.4 mm. Echocardiographic epicardial adipose tissue was significantly correlated with whole-body glucose uptake index from the clamp and with all indices of insulin resistance and glucose intolerance measured, except the 120-min plasma glucose level after an oral glucose tolerance test.
CONCLUSIONS: Our study showed that the epicardial fat is significantly related to obesity-related insulin resistance. This finding could be of potential interest in clinical practice and research of obesity-related risk stratification.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16091479     DOI: 10.1210/jc.2005-1087

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  95 in total

Review 1.  Epicardial adipose tissue in endocrine and metabolic diseases.

Authors:  Gianluca Iacobellis
Journal:  Endocrine       Date:  2013-11-23       Impact factor: 3.633

Review 2.  Do cardiac and perivascular adipose tissue play a role in atherosclerosis?

Authors:  Gianluca Iacobellis; Yu-Jing Gao; Arya M Sharma
Journal:  Curr Diab Rep       Date:  2008-02       Impact factor: 4.810

Review 3.  Cardiovascular effects of leptin.

Authors:  Gary Sweeney
Journal:  Nat Rev Cardiol       Date:  2009-12-01       Impact factor: 32.419

Review 4.  Metabolic syndrome and lifestyle modification.

Authors:  Mitsuyoshi Takahara; Iichiro Shimomura
Journal:  Rev Endocr Metab Disord       Date:  2014-12       Impact factor: 6.514

Review 5.  Local and systemic effects of the multifaceted epicardial adipose tissue depot.

Authors:  Gianluca Iacobellis
Journal:  Nat Rev Endocrinol       Date:  2015-04-07       Impact factor: 43.330

Review 6.  Perivascular adipose tissue: epiphenomenon or local risk factor?

Authors:  K Schäfer; I Drosos; S Konstantinides
Journal:  Int J Obes (Lond)       Date:  2017-05-22       Impact factor: 5.095

7.  Targeting the organ-specific adiposity.

Authors:  Gianluca Iacobellis; Giuseppe Barbaro
Journal:  Eat Weight Disord       Date:  2018-08-14       Impact factor: 4.652

Review 8.  Insulin Resistance and Atherosclerosis: Implications for Insulin-Sensitizing Agents.

Authors:  Antonino Di Pino; Ralph A DeFronzo
Journal:  Endocr Rev       Date:  2019-12-01       Impact factor: 19.871

9.  Pericardial adipose tissue, atherosclerosis, and cardiovascular disease risk factors: the Jackson heart study.

Authors:  Jiankang Liu; Caroline S Fox; Demarc Hickson; Daniel Sarpong; Lynette Ekunwe; Warren D May; Gregory W Hundley; J Jeffery Carr; Herman A Taylor
Journal:  Diabetes Care       Date:  2010-04-22       Impact factor: 17.152

10.  Obesity and preclinical changes of cardiac geometry and function.

Authors:  Joong Kyung Sung; Jang-Young Kim
Journal:  Korean Circ J       Date:  2010-02-23       Impact factor: 3.243

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.